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Abstract: The locus coeruleus (LC), the major noradrenergic nucleus of the brain, gives rise to fibres innervating most 
structures of the neuraxis. Recent advances in neuroscience have helped to unravel the neuronal circuitry controlling a 
number of physiological functions in which the LC plays a central role. Two such functions are the regulation of arousal 
and autonomic activity, which are inseparably linked largely via the involvement of the LC. Alterations in LC activity due 
to physiological or pharmacological manipulations or pathological processes can lead to distinct patterns of change in 
arousal and autonomic function. Physiological manipulations considered here include the presentation of noxious or anxi-
ety-provoking stimuli and extremes in ambient temperature. The modification of LC-controlled functions by drug admini-
stration is discussed in detail, including drugs which directly modify the activity of LC neurones (e.g., via autoreceptors, 
storage, reuptake) or have an indirect effect through modulating excitatory or inhibitory inputs. The early vulnerability of 
the LC to the ageing process and to neurodegenerative disease (Parkinson’s and Alzheimer’s diseases) is of considerable 
clinical significance. In general, physiological manipulations and the administration of stimulant drugs, 2-adrenoceptor 
antagonists and noradrenaline uptake inhibitors increase LC activity and thus cause heightened arousal and activation of 
the sympathetic nervous system. In contrast, the administration of sedative drugs, including 2-adrenoceptor agonists, and 
pathological changes in LC function in neurodegenerative disorders and ageing reduce LC activity and result in sedation 
and activation of the parasympathetic nervous system.  
Key Words: Locus coeruleus, arousal, autonomic function, noxious stimuli, anxiety, Parkinson’s disease, Alzheimer’s disease, 
aging. 
Abbreviations: 6-OHDA, 6-hydroxydopamine; AD, Alzheimer’s disease; BF, Basal forebrain; CR, Caudal raphe; CS, Condi-
tioned stimulus; DMV, Dorsal motor nucleus of the vagus; DR, Dorsal raphe; EDS, Excessive daytime sleepiness; EEG, Elec-
troencephalogram; EMG, Electromyogram; EWN, Edinger-Westphal nucleus; fMRI, Functional magnetic resonance imaging; 
GABA, Gamma-aminobutyric acid; LC, Locus coeruleus; LDT, Laterodorsal tegmental nucleus; MPTP, 1-methyl-4-phenyl- 
1,2,3,6- tetrahydropyridine; PD, Parkinson’s disease; PPT, Pedunculopontine tegmental nucleus; PST, Pupillographic sleepi-
ness test; PVN, Paraventricular nucleus; REM, Rapid eye movement; RVLM, Rostroventrolateral medulla; SWS, Slow wave 
sleep; US, Unconditioned stimulus; VLPO, Ventrolateral preoptic area; VTA, Ventral tegmental area. 
1. BRIEF OUTLINE OF THE ROLE OF THE LOCUS 
COERULEUS IN THE MAINTENANCE OF 
AROUSAL AND REGULATION OF AUTONOMIC 
FUNCTIONS 
  The LC, the largest group of noradrenergic neurones in 
the central nervous system, is a major nucleus involved in 
the neural pathways controlling arousal and autonomic func-
tion. These physiological functions are inseparably linked, 
largely due to the central role of the LC in controlling these 
functions. The LC projects extensively to widespread areas 
of the neuraxis (see Part I) and these projections can result in 
both excitatory effects via the activation of 1-adrenoceptors 
and inhibitory effects via the stimulation of 2-adrenoceptors 
[206]. Therefore, complex changes in the neural circuitry 
underlying arousal and autonomic function result from 
changes in LC activity. 
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1.1. Arousal 
  The LC is recognised as a major wakefulness-promoting 
nucleus [304, 305], where the activity of the LC closely cor-
relates with level of arousal [16, 17, 18, 122, 123, 355, 360]. 
This wakefulness-promoting action results from the dense 
projections from the LC to most areas of the cerebral cortex 
[208] and from the multitude of projections from the LC to 
alertness-modulating nuclei (see Part I). The LC exerts an 
excitatory influence on wakefulness-promoting neurones 
such as cholinergic neurones of the BF [111, 126, 203, 205] 
and of the PPT and LDT nuclei [26], cortically-projecting 
neurones of the thalamus [280, 281] and serotonergic neu-
rones of the DR [219, 309, 375], and an inhibitory influence 
on sleep-promoting GABA-ergic neurones of the BF [268, 
288, 451] and VLPO of the hypothalamus [74, 288, 319]. 
Thus, increases in LC activity result in increases in EEG 
signs of alertness [29] whilst inactivation of the LC reduces 
this EEG activity [30, 91], demonstrating a reduction in 
alertness. Furthermore, the LC exerts a powerful inhibitory 
influence on REM sleep, probably by inhibiting a subgroup Functional Neuroanatomy of the Noradrenergic Locus Coeruleus  Current Neuropharmacology, 2008, Vol. 6, No. 3    255
of cholinergic neurones in the pedunculopontine tegmental 
nucleus involved in REM sleep [185] (see Part I). Indeed, 
electrical stimulation of the LC has been found to reduce the 
quantity of SWS and REM sleep in a human subject [211], 
demonstrating an increase in wakefulness. A schematic dia-
gram outlining the sleep/arosal neuronal network, highlight-
ing the central position of the LC, is shown in Fig. (1). 
1.2. Autonomic Functions 
  It is also well recognised that the LC plays an important 
role in controlling autonomic functions (see Part I). As a 
major premotor autonomic nucleus, the LC sends direct pro-
jections to the sympathetic preganglionic neurones in the 
spinal cord [208, 316, 489] and parasympathetic pregangli-
onic neurones in the brainstem and spinal cord (EWN: [50, 
255]; salivatory nuclei: [203, 419]; DMV: [309, 457, 490]; 
nucleus ambiguus: [208, 490]; spinal cord: [208, 385, 490, 
506]). It should be noted that the DMV also contains soma-
tomotor neurones to varying degrees in different mammalian 
species [256], and in fact in humans it is almost completely 
somatmotor. [52]. On the other hand, the EWN is an almost 
exclusively preganglonic parasympathetic nucleus in man 
[52]. In general, the LC increases sympathetic activity via
the activation of 1-adrenoceptors on preganglionic sympa-
thetic neurones [248] and reduces parasympathetic activity 
via the activation of 2-adrenoceptors on preganglionic para-
sympathetic neurones [418, 465, 501]. Furthermore, the LC 
also exerts an indirect effect on autonomic activity via pro-
jections to other premotor autonomic nuclei such as the PVN 
[207, 208, 309, 440, 461], the RVLM [470], and the CR 
[174, 208]. It is of interest that while the influence of the LC 
on premotor autonomic neurones in the PVN and CR is exci-
tatory, it is inhibitory on neurones in the RVLM (see Fig. 
(2)). Finally, the LC may modulate autonomic activity by 
projections to the cerebral cortex and amygdala [208, 293], 
structures which are known to influence the activity of pre-
motor sympathetic neurones in the PVN [173, 420] and 
RVLM [437]. The projections of the LC to the amygdala 
[90, 218] and to the PVN [381, 430] have both been linked 
to the autonomic response to stress, consisting of generalised 
sympathetic activation. A schematic diagram outlining the 
autonomic neuronal network, highlighting the central posi-
tion of the LC, is shown in Fig. (2). 
  The activation of the LC results in a well-defined pattern 
of autonomic changes: in tissues receiving a predominantly 
sympathetic innervation (e.g., arterioles and sweat glands) 
there is an increase in activity, whereas in those receiving 
predominantly parasympathetic innervation (e.g., salivary 
glands) there is a decrease in activity. It should be noted that 
the pressor effect observed after LC activation is attenuated 
by the inhibition of the RVLM [470], resulting in only mod-
erate increases in heart rate and blood pressure [412, 482]. 
Furthermore, in a tissue receiving a dual sympathetic/para-
sympathetic innervation (e.g., iris), where the two autonomic 
inputs have opposing effects, the effect of LC activation on 
sympathetic activity is enhanced by the inhibition of the 
parasympathetic output. The consequences of LC activation 
Fig. (1). Schematic diagram of the connections within the arousal-controlling neuronal network. Wakefulness-promoting nuclei (grey): TMN, 
tuberomamillary nucleus; LH/PF, lateral hypothalamic/perifornical area; Th, thalamus; LC, locus coeruleus; VTA, ventral tegmental area; 
PPT, pedunculopontine tegmental nucleus; R, raphe nuclei. Sleep-promoting nucleus (hatched): VLPO, ventrolateral preoptic nucleus. 
GABAergic interneurones, in (white). Neurotransmitters: ACh, acetylcholine; NA, noradrenaline; H, histamine; Ox, orexin; GABA, -
aminobutyric acid; DA, dopamine; 5HT, 5-hydroxytryptamine; Glu, glutamate. Receptors: 1, excitatory 1-adrenoceptors; 2, inhibitory 2-
adrenoceptors; H1, excitatory H1 histamine receptors; 5HT2A and 5HT2C, excitatory 5HT receptors. Neuronal outputs: excitatory (solid ar-
rows) and inhibitory (broken arrows). The wakefulness-promoting nuclei exert a direct activating effect on the cerebral cortex; the VLPO 
promotes sleep by inhibiting the TMN and the LC. The LC promotes wakefulness by stimulating the cerebral cortex and the wakefulness-
promoting neurones of the PPT, and by inhibiting the VLPO. The LC also inhibits the REM-sleep-promoting neurones of the PPT. The raphe 
nucleus promotes wakefulness by activating the cerebral cortex; this effect is attenuated by stimulation of GABAergic interneurones, which 
inhibit the LC and the VTA. The VTA exerts its wakefulness-promoting effect largely via activation of the LC, and the LH/PF largely via
activation of the TMN and the LC. The connections of the LC are reviewed in detail in Part I. The GABAergic interneurones, activated by 
excitatory 5HT2C receptors, are located in the VTA itself [55, 140] and in the vicinity of the LC [140]. Modified with permission from Sza-
badi, 2006. 
Cortex
TMN LH
/PF
VLPO
VTA
LC
PPT
REM
sleep
Hypo-
thalamus
Brainstem
GABA
NA
H Ox
DA
NA
Ox
Ox
Ox
NA
NA
H
in
DA
R
GABA
GABA 5HT
5HT
5HT2A a1 1 H
a1 5HT2C
a2
a2
GABA
ACh
Th
Glu256    Current Neuropharmacology, 2008, Vol. 6, No. 3 Samuels and Szabadi 
are, therefore, observable as an increase in pupil diameter 
[341, 342], attenuation of the light reflex response [22, 38, 
40], moderate increases in heart rate and blood pressure 
[106, 154, 251, 412, 429, 482], suppression of the baroreflex  
response [192, 401], and a reduction in salivation [446]. The 
modulation of the baroreflex response by the LC may reflect 
to some extent the activity of central adrenergic neurones 
which have been shown to project to the LC (see Section  
Fig. (2). The central role of the locus coeruleus (LC) in the regulation of autonomic functions. Nuclei: PVN, paraventricular nucleus; Pre ggl 
Para, preganglionic parasympathetic neurones; EW, Edinger-Westphal nucleus; Saliv, salivatory nucleus; Pre ggl Symp, preganglionic sym-
pathetic neurones; Symp ggl, sympathetic ganglion; Para ggl, parasympathetic ganglion. Neurotransmitters: NA, noradrenaline; ACh, acetyl-
choline. Receptors: 1 and 2, adrenoceptor subtypes. Symbols: +, excitatory, -, inhibitory. Organs comprising of smooth muscle (e.g., blood 
vessels, iris), or glandular tissue (e.g., sweat glands, salivary glands) receive autonomic (sympathetic and parasympathetic) innervations. 
Both innervations consist of a chain of two neurones (preganglionic and postganglionic) joined in a synapse located in the autonomic gan-
glion. Preganglionic sympathetic neurones are located in the intermediolateral cell column (IML) of the spinal cord whereas the pregangli-
onic parasympathetic neurones are located in brainstem nuclei. Blood vessels (arterioles) and sweat glands receive sympathetic and salivary 
glands parasympathetic inputs whereas the smooth muscles in the iris are controlled by opposing sympathetic and parasympathetic inputs. 
The preganglionic neurones are always cholinergic, the postganglionic sympathetic neurones are noradrenergic, with the exception of those 
innervating the sweat glands which are cholinergic, whereas the postganglionic parasympathetic neurones are always cholinergic. The 
preganglionic neurones are influenced by premotor autonomic nuclei of which three are shown (PVN, vasomotor neurones located in the 
rostroventrolateral medulla, and the LC). The LC plays a pivotal role in autonomic regulation, influencing the activities of preganglionic 
neurones both directly and indirectly via the PVN and vasomotor neurones. The outputs from the LC can activate either excitatory 1-
adrenoceptors or inhibitory 2-adrenoceptors. The output from the LC to the PVN is largely to its parvicellular subdivision; this connection 
plays a relatively minor role. The LC exerts an excitatory effect on preganglionic sympathetic neurones and an inhibitory effect on vasomo-
tor premotor neurones and on preganglionic parasympathetic neurones. The activity of the preganglionic neurones is under the influence of 
the cerebral cortex. The light reflex is a parasympathetically-mediated reflex consisting of the constriction of the pupil in response to a light 
stimulus reaching the retina. The neuronal chain in the reflex includes the pretectal nucleus, the EW, and the ciliary ganglion. The connec-
tions of the LC shown in this figure are discussed in detail in Part I. 
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3.1.4.5 in Part I) and to be sensitve to changes in blood pres-
sure [252]. 
1.3. Correlation between Arousal and Autonomic Func-
tion 
  The central role of the LC in the combined regulation of 
arousal and autonomic function is highlighted by the associa-
tion between the level of arousal in pupillary activity. It has 
been shown that changes in the level of arousal are associ-
ated with changes in pupil diameter [186, 254] and sponta-
neous pupillary fluctuations in darkness [257, 507], and there 
is evidence that the pupillary changes directly reflect LC 
activity [354]. Indeed, the close relationship between level of 
arousal and pupil diameter has been exploited in the PST, 
which records pupil diameter over a period of eleven min-
utes. During the period of recording slow fluctuations appear 
in the diameter of the pupil (“pupillary fatigue waves”), and 
it has been shown that the power of these fluctuations can be 
used as a reliable index of the level of arousal [493]. As there 
is a close parallelism between fluctuations in the firing rates 
of LC neurones and fluctuations in pupil diameter (see Fig. 
(3)), it is likely that the pupillary fatigue waves represent 
fluctuations in LC activity, and thus may provide a direct 
Fig. (3). A: Relationship between pupil diameter and the firing rate of an LC neurone in a monkey. The two recordings were taken simulta-
neously. There was a clear parallelism between fluctuations in pupil diameter and firing rate. Reproduced with permission from Aston-Jones 
and Cohen (2005). B: An example recording from the pupillographic sleepiness test (PST) demonstrating fluctuations in resting pupil diame-
ter (top) and the power spectrum (bottom) over an 11-minute recording period. The data for the total time period are divided into eight equal 
bins for further analysis. The fluctuations in resting pupil diameter are used in the analysis of the pupillary unrest index (PUI), the distance 
for which the margin of the pupil travels in one minute. The mean value of PUI obtained for the whole recording period is shown on the right 
of the figure. Vertical axis: pupil diameter (mm), horizontal axis: time (min). The mean pupil diameter for each bin is displayed above the 
horizontal axis, with the average diameter over the total recording period shown on the right of the figure. The mean PUI for each bin is dis-
played above the recording. The power spectrum is used in a Fast Fourier Transform analysis to derive a measure of total power (arbitrary 
units), shown on the right of the figure. Power (arbitrary units) is displayed along the vertical axis and frequency (Hz) is displayed along the 
horizontal axis for each time-bin individually. The total power for each bin is displayed above the power spectrum. 
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physiological indicator of the functioning of this important 
brainstem nucleus. 
1.4. Scope of the Review 
  The activity of the LC can be altered through a variety of 
physiological manipulations such as the presentation of a 
noxious or anxiety-provoking stimulus or by variations in 
ambient temperature, through pharmacological manipula-
tions such as the administration of drugs which act directly at 
the autoreceptors located on the neurones of the LC, that 
modify the reuptake or storage of noradrenaline, or that act 
indirectly to modify LC activity, through neuronal loss from 
the LC in aging, and through pathological changes that occur 
as a result of neurodegenerative disease (PD, AD) and brain-
stem trauma resulting in coma. In this review we attempt to 
delineate the effects of experimental manipulations and 
pathological changes on LC activity and hence on level of 
arousal and autonomic function. 
2. PHYSIOLOGICAL MANIPULATION OF LOCUS 
COERULEUS ACTIVITY 
  LC neurone activity is determined by a number of varied 
inputs, as described in our companion paper (see Part I). 
Physiological manipulations, such as the presentation of a 
noxious or anxiety-provoking stimulus or an extreme in am-
bient temperature, can modulate the strength of these inputs, 
and therefore the extent of excitation or inhibition of the 
noradrenergic neurones, to alter the overall activity of the 
LC. The effect on LC activity resulting from these manipula-
tions can often be detected via the measurement of resting 
pupil diameter and/or pupillary reflexes to sudden light stim-
uli, since the LC is so integral to pupillary control [444]; see 
above and Part I. For changes in cortical activity following 
LC activation, see Section 2.1.1. in Part I. 
2.1. Noxious Stimuli 
  The LC is innervated by the sensory neurones of the dor-
sal horn of the spinal cord: this innervation provides a 
method of communicating nociceptive information to this 
nucleus [61, 82, 309]; see 3.1.6, Part I. Neurone activity 
within the LC is increased following the presentation of a 
noxious stimulus, measurable as an increase in electrical 
activity [109, 124, 220, 361, 412] and an increase in c-fos 
expression [56, 326, 327, 340, 394, 462, 478]; see [324] for a 
review. The pattern of LC neurone firing after the presenta-
tion of a noxious stimulus involves an initial burst of activity 
followed by a period of quiescence [420]. Interestingly, mi-
croinjection of the 2-adrenoceptor antagonist idazoxan into 
the LC, which is likely to result in an increase in LC activity 
(see section 3.2, below), has been reported to increase the 
responsiveness of LC neurones to noxious stimulation [420]. 
In addition, noradrenaline levels in both the LC and PVN, a 
projection area of the LC (see 2.2.2.2, part I), are increased 
following noxious stimulation [324, 374, 411], presumably 
as a result of an increase in noradrenaline synthesis in LC 
neurones. Indeed, the PVN has been implicated in pain per-
ception. Interestingly, the increase in LC activity following 
the presentation of a noxious stimulus has been found to in-
hibit neurones of the basolateral nucleus of the amygdala and 
this inhibition may be involved in the formation of emotional 
memories following a noxious event [70]. 
  It is expected that an increase in LC activity following 
noxious stimulation would, in general, increase sympathetic 
and decrease parasympathetic activity (see section 1.2, 
above), and this may be related to the paradigm of pupillary 
reflex dilatation, the best studied autonomic response to nox-
ious stimulation. Pupillary reflex dilatation is observable in 
both experimental animals [177, 231] and human subjects 
[66, 237, 481, 504]. 
  Interestingly, drugs that are known to modify LC activity 
(see 3.2, below) also affect pupillary reflex dilatation in a 
way consistent with the alteration in LC activity. Thus, ma-
nipulations which decrease LC activity in experimental ani-
mals (e.g., monoamine depletion by reserpine and alpha-
methyl-para-tyrosine) antagonise pupillary reflex dilatation 
[175]. However, paradoxically, both an 2-adrenoceptor an-
tagonist, yohimbine [175, 177] and an 2-adrenoceptor ago-
nist, dexmedetomidine [237] have been reported to inhibit 
pupillary reflex dilatation. As the observations with yo-
himbine were made in cats and those with dexmedetomidine 
in humans, these findings can be reconciled by a well-
documented species difference in the pupillary effects of 
drugs interacting with 2-adrenoceptors. It has been shown 
that agonists constrict and antagonists dilate the pupil in man 
but evoke effects in the opposite direction in cats, indicating 
the preferential action of these drugs at pre-synaptic 2-
adrenoceptors in man and post-synaptic 2-adrenoceptors in 
the cat (see 3.2, below). In both man and the cat, the admini-
stration of an 2-adrenoceptor antagonist is expected to acti-
vate the LC and increase its sensitivity to further activation 
by noxious stimulation [409], which would be expected to 
lead to facilitation of pupillary reflex dilatation. However, in 
the cat this effect is likely to be masked by miosis, resulting 
from the activation of the EWN as a result of the blockade of 
post-synaptic inhibitory 2-adrenoceptors, leading to the ap-
parent attenuation of pupillary reflex dilatation. On the other 
hand, the 2-adrenoceptor agonist is expected to reduce LC 
activity and thus attenuate the LC activation resulting from 
the noxious stimulation, manifesting as an apparent reduc-
tion in pupillary reflex dilatation. Indeed, this effect has been 
reported in man [237]. It should be noted that Larson and 
Talke [237] interpreted this finding on the basis of a postu-
lated anti-nociceptive effect of dexmedetomidine, since they 
assumed that the LC had been completely “switched off” by 
the pre-treatment of their subjects with opiates. 
  A well-studied experimental paradigm of sympathetic 
activation by noxious stimulation in human subjects is the 
cold pressor test, evoked by a painful cold stimulus to the 
hand, which leads to both an increase in blood pressure and 
to pupil dilatation [454, 455]. This response has two interest-
ing features. Firstly, it is not accompanied by a reduction in 
light reflex amplitude [455], as would be expected on the 
basis of increased LC activity, which could be predicted to 
lead to enhanced noradrenergic inhibition of the EWN. This 
observation raises the possibility that different populations of 
LC neurones may be responsible for mediating the sympa-
thetic activating and parasympathetic inhibiting effects of the 
LC on pre-ganglionic autonomic neurones (see 5, below), 
where the cold pressor test may influence only the sympa-
thetic pre-autonomic neurones in the LC. Secondly, while 
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can be antagonised by diazepam, the increase in pupil diame-
ter is resistant to it [189]. This observation may indicate that 
different structures may be involved in mediating the auto-
nomic effects of the cold pressor test, the pupillary effect is 
likely to be mediated by the LC whereas the pressor effect by 
the PVN. Furthermore, while GABAA receptors occur in 
both the LC [71, 216, 314] and the PVN [158, 162, 212, 
467], those in the LC are insensitive to diazepam [71], 
whereas those in the PVN, like GABAA receptors in general, 
probably are sensitive to this drug. 
2.2. Anxiety 
  Anxiety is generally defined as an emotional state evoked 
by threatening stimuli, although pharmacological interven-
tion can also produce increased anxiety levels [443]. It is 
known that the amygdala is critical to the generation of anxi-
ety and anxious responses [90, 218, 242] and there is a two-
way excitatory connection between the amygdala and the LC 
(see Part I). It, therefore, follows that LC activation could be 
expected to lead to anxiety through the activation of the 
amygdala and, conversely, anxiety producing stimuli that 
increase the activity of the amygdala could be expected to 
lead to LC activation. This circular argument makes it diffi-
cult to determine in a given situation whether anxiety is pro-
duced by the activation of the LC or whether the LC is acti-
vated as a result of increased anxiety. In certain situations, 
however, the two processes can be delineated (see below). 
2.2.1. Anxiogenic Effect of LC Activation 
  Electrical stimulation of the LC evokes fear-related be-
havioural responses [365], which can be alleviated by 
clonidine, morphine, and diazepam [365], drugs known to 
suppress LC activity (see sections 3.1 and 3.2). Administra-
tion of the 2-adrenoceptor antagonist yohimbine activates 
the LC (see section 3.2), which in turn produces an increase 
in anxiety [141, 282, 300, 453]. Conversely, bilateral lesions 
of the LC [363] or of the ascending noradrenergic projection 
arising from it [475], lead to a reduction in fear-related re-
sponses. 
2.2.2. LC Activation by States of Anxiety 
  It is well recognized that patients suffering from different 
forms of anxiety disorder show evidence of altered auto-
nomic regulation [443]. Many of the changes reported are 
consistent with increased LC activity, leading to enhance-
ment of sympathetic discharge and inhibition of parasympa-
thetically mediated functions. Thus, it has been reported that 
anxious patients show hypersensitivity of their eccrine sweat 
glands to intradermally injected muscarinic cholinoceptor 
agonists, such as carbachol, a finding indicating increased 
sympathetic activity. Eccrine sweat glands receive a cho-
linergic sympathetic innervation (see Fig. (2)), and their ac-
tivity, and also their sensitivity to cholinoceptor agonists, is 
modulated by impulse traffic in the sympathetic fibres, high 
firing rates being associated with high, and low firing rates 
with low sweat gland activity/sensitivity [443]. Furthermore, 
it has been shown that patients suffering from generalized 
anxiety disorder have attenuated light reflexes [22], consis-
tent with increased noradrenergic inhibition of the EWN 
originating from the LC. 
  Experimental situations of induced fear increase anxiety 
via the activation of the amygdala and lead to LC activation 
[68, 69, 85, 360, 364]. The experimental paradigm of condi-
tioned fear can be used to produce states of fear and anxiety 
in the laboratory and thus can be used to assess the modula-
tion of the LC during these states. Fear conditioning, where a 
neutral stimulus (CS) is temporally associated with an aver-
sive stimulus (US) and thus gains an aversive character it-
self, produces an increase in LC activity as demonstrated by 
increased c-fos expression when the CS is presented alone 
[195, 253]. In addition, rats selectively bred to demonstrate 
high levels of anxiety show increased c-fos expression 
within the LC [376] and in human volunteers subliminal fear 
signals have been found to elicit activity within the LC, as 
detected by functional neuroimaging [250]. 
  The increase in LC activity following the conditioned 
fear paradigm is accompanied by an increase in arousal and 
sympathetic function. For example, REM sleep has been 
observed to concomitantly decrease in response to the pres-
entation of a fear conditioned stimulus [253] and this is con-
sistent with the activation of the LC and the expected in-
crease in arousal. The activation of the sympathetic nervous 
system by conditioned fear results in a variety of changes in 
autonomic activity and in particular there are two measurable 
changes in the pupil: an increase in resting pupil diameter 
and a reduction in the amplitude of the light reflex response 
[36, 38, 39, 40, 42]. Furthermore, it has been reported that 
patients suffering from generalised anxiety disorder have 
attenuated light reflex responses [22]. These pupillary effects 
are likely to reflect the dual influence of LC activation on the 
pupil: the increase in resting pupil diameter may suggest an 
increase in sympathetic outflow and/or a decrease in para-
sympathetic outflow to the iris, whereas the decrease in light 
reflex amplitude is the result of inhibition of the parasympa-
thetic outflow to the iris (see above). Interestingly, of the two 
pupillary effects of conditioned fear, evoked by the threat of 
a mild electric shock, only the reduction in light reflex re-
sponse amplitude was related quantatively to the degree of 
subjective anxiety, whereas the increase in pupil diameter 
was not [42], and only the reduction in light reflex response 
amplitude was susceptible to antagonism by the anxiolytic 
drug diazepam, whereas the increase in pupil diameter was 
not [36, 40]. These observations suggest that conditioned 
fear may preferentially activate the pre-parasympathetic neu-
rones in the LC via the amygdala, leading to the anxiety-
dependent reduction in light reflex response amplitude, 
whereas it may cause some indirect activation of the pre-
sympathetic neurones via the arousal system, resulting in 
some increase in pupil diameter. The differential effects of 
diazepam on the two components of the pupillary anxiety 
response may reflect the fact that diazepam may increase the 
GABAergic inhibition of amygdala neurones, thus leading to 
the attenuation of the fear-induced activation of pre-para-
sympathetic LC neurones, whereas it may not be able to 
modify the activity of pre-sympathetic LC neurones which 
do not contain diazepam-sensitive GABA receptors [71]; see 
also Section 3 and Fig. (6).  
  Stress exposure, which may also be classed as an anxi-
ety-provoking situation, is also associated with enhanced LC 
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453, 101, 322, 323], following the presentation of a stressful 
stimulus in experimental animals, such as the rat and cat 
Indeed, chronic stress exposure produces long-term altera-
tions in LC firing and noradrenaline release [51, 398, 321, 
322]. For reviews on the activation of the central noradren-
ergic system by exposure to stressful stimuli, see refs. 324, 
328; see also Section 2.1. 
  The enhancement of LC activity by stressful stimuli can 
be detected by changes observed in autonomic activity. 
Tasks inducing stress via high levels of cognitive load have 
been found to increase pupil diameter and reduce light reflex 
amplitude compared to no or low cognitive load tasks [426, 
427]. Furthermore, these studies have identified both an in-
crease in sympathetic activity and a decrease in parasympa-
thetic activity in the modulation of pupil diameter following 
the application of a cognitive load, consistent with LC acti-
vation. Recently it has been shown that remembering emo-
tionally-loaded material results in activation of the LC in 
humans, as detected by functional magnetic resonance imag-
ing (fMRI), together with an increase in pupil diameter 
[428]. 
2.2.3. Role of the LC in Mediating Fear Responses 
  It has been proposed that an increase in LC activity me-
diates the behavioural responses associated with fear and 
anxiety [67], and this is supported by observations associat-
ing the increased firing of the LC following the presentation 
of fear-inducing stimuli with behavioural manifestations of 
fear [51]. For example, 2-adrenoceptor knockout mice lack-
ing the physiological brake of LC activity (see section 3.2) 
show both an increase in LC activity and an increase in 
freezing responses in the conditioned fear paradigm [92], 
whilst lesions of the LC attenuate the freezing response both 
to the unconditioned aversive stimulus and to the condi-
tioned cue [306].  
  An interesting possibility that results from the interaction 
of the amygdala and the LC (see above) is that activation of 
the LC may contribute to the fear-potentiated startle re-
sponse. The startle response involves rapid involuntary con-
tractions of facial and skeletal musculature in response to a 
sudden intense stimulus, for example, a loud sound, and this 
reaction is measurable in man as an EMG response from the 
orbicularis oculi muscle (eyeblink startle response). The LC 
is likely to be involved in modulating the startle response 
since the LC projects to the motoneurones in the facial nu-
cleus [208]; see 2.3.5.1, Part I, which innervates the orbicu-
laris oculi muscle. This projection is likely to exert a facilita-
tory influence on the motoneurones as demonstrated by the 
enhancement of motoneurone activity evoked by the ex-
tracellular microiontophoretic application of noradrenaline to 
the facial motoneurones [359, 471, 491]. The administration 
of an 2-adrenoceptor agonist, which reduces LC activity, 
has been found to reduce the startle response [3, 4, 233, 379], 
whereas the 2-adrenoceptor antagonist yohimbine, which is 
known to enhance LC activity [200, 413, 453], enhances the 
amplitude of the acoustic startle response [294]. It is possible 
that this modulation of the startle response arises from the 
withdrawal or potentiation of the excitatory input to the or-
bicularis oculi muscle from the LC, leading to a reduction or 
enhancement in the tone of this muscle respectively [379]. 
Indeed, the wakefulness-promoting drug modafinil, assumed 
to act through enhancing the activity of the LC [184, 383]; 
see also 3.2.1.2, was found to antagonise the reduction in 
startle response amplitude found following clonidine admini-
stration [379]. 
  This startle response can be potentiated by the threat of 
an electric shock, inducing a state of fear via the activation 
of the amygdala [93]. This paradigm is therefore used as an 
important laboratory model of anxiety, both in animals [301, 
369, 408, 498] and humans [11, 144, 147, 210]. The LC may 
contribute to the activation of the startle pathway in the fear-
potentiated startle paradigm in two ways. Firstly, the acous-
tic stimulus itself may prime motoneurone activity via the 
LC: the acoustic stimulus leads to the activation of the cau-
dal pontine reticular nucleus, the major pre-motor integrator 
of the startle response [226], which activates not only the 
facial motoneurones but also the LC [379], which in turn 
results in the facilitation of motoneurone activity (see 
above). Secondly, the activation of the amygdala by fear-
conditioning may increase LC activity (see above) and thus 
the noradrenergic output of this nucleus. In this way, the dual 
excitatory input to the LC from the caudal pontine reticular 
nucleus and the amygdala enhances the tone of the motoneu-
rones of the facial nucleus and contributes to the fear-
potentiated startle response. Interestingly, the administration 
of the 2-adrenoceptor agonist clonidine, which reduces LC 
activity, has been found to result in a reduction in the fear-
potentiated startle response [94], whilst the administration of 
the 2 adrenoceptor antagonist yohimbine, which is known to 
enhance LC activity, enhances the fear-potentiated startle 
response [94]. 
2.3. Ambient Temperature 
  Preoptic nuclei of the hypothalamus, including the 
VLPO, are intimately involved in temperature regulation 
[108, 387], and neurones in these areas change their activi-
ties in response both to increases and decreases in body tem-
perature [108]. Body temperature in turn may be influenced 
by ambient temperature [15]. Furthermore, neurones in the 
VLPO project profusely to the LC (see 3.1.3.1, Part I). 
Therefore, shifts in ambient temperature induce changes in 
LC activity via the mediation of the anterior hypothalamus.  
  Acute and chronic modulation of ambient temperature 
has different effects on LC activity, acute temperature chan-
ges increasing and chronic exposure decreasing LC activity. 
The increase in LC activity in response to acute cold stress 
has been demonstrated as increases in c-fos expression [223, 
508] and in the activity of the rate-limiting enzyme in 
noradrenaline synthesis, tyrosine hydroxylase [72, 320]. 
Similarly, acute high ambient temperature increases LC neu-
rone activity [295]. Activation of the LC by high ambient 
temperature (40°C) is associated with activation of the sym-
pathetic nervous system, manifesting as increases in body 
temperature, heart rate, carbachol-evoked sweating, and 
physiological finger tremor [15] and a reduction in the re-
covery time of the pupillary light reflex response [247]. 
Some of these sympathetic responses (increases in body 
temperature and heart rate) could be antagonised by 
clonidine [15] consistent with the involvement of the LC. In 
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LC neurone firing [223]. It is of interest to note that acute 
thermal cutaneous stimulation also activates neurones of the 
LC, via the release of excitatory amino acids from the nu-
cleus paragigantocellularis [153]. 
  Chronic cold stress has been found to reduce LC neurone 
activity, measurable as a reduction in tyrosine hydroxylase 
activity and an increase in 2-adrenoceptor mRNA expres-
sion in the LC [113]. Similarly, chronic high ambient tem-
perature reduces LC activity, measurable as a reduction in 
tyrosine hydroxylase activity [130]. 
3. PHARMACOLOGICAL ALTERATIONS OF LO-
CUS COERULEUS ACTIVITY 
  Drugs can modify LC activity either directly by interact-
ing with different aspects of the function of the noradrener-
gic neurones, i.e. by modifying firing rate and/or release via
an action at inhibitory autoreceptors, modifying the storage 
of the neurotransmitter in presynaptic vesicles, and interfer-
ing with the elimination of synaptically released noradrena-
line via the reuptake mechanism. Drugs may also have an 
indirect effect on LC activity via the modification of the ac-
tivities of excitatory or inhibitory inputs to the LC.  
3.1. Drugs with a Direct Action on LC Activity 
3.1.1. Drugs Acting at Autoreceptors 
  LC neurone activity can be modulated via the administra-
tion of drugs that stimulate or block the inhibitory autorecep-
tors located presynaptically on the LC neurones (see 3.2, Part 
I). Autoreceptors occur both on the cell body (somatoden-
dritic autoreceptors) and at the nerve ending (terminal auto-
receptors). The somatodendritic autoreceptors modulate the 
firing rate of the neurone whereas the terminal autoreceptors 
modulate the release of the neurotransmitter. Exposure to the 
2-adrenoceptor agonist clonidine has been used to activate 
these autoreceptors, whilst the 2-adrenoceptor antagonist 
yohimbine has been used to block them. Administration of 
clonidine to the LC hyperpolarises the neuronal membrane 
via an increase in potassium conductance leading to a reduc-
tion of the spontaneous firing rate of the neurones, resulting 
in the inhibition of the LC [5, 6, 114, 273, 303, 438, 439, 
494, 496]. The inhibition of LC activity by clonidine is ac-
companied by a fall in plasma noradrenaline concentration 
[182]. Other 2-adrenoceptor agonists such as dexmede-
tomidine have a similar effect on LC activity [73, 209]. In 
contrast, administration of yohimbine to the LC increases 
neuronal firing [200, 300, 303, 413, 453] and noradrenaline 
release[487]. Other 2-adrenoceptor antagonists (BRL44408, 
RS79948, RX821002) have also been found to have an exci-
tatory influence on the LC, observable as an increase in 
noradrenaline release at LC terminal regions [115]. 
  Noradrenergic pathways arising from the LC may medi-
ate either excitatory effects, via the activation of 1-
adrenoceptors, on the target cells (ie. in the cerebral cortex 
and IML) or inhibitory effects, via the activation of 2-
adrenoceptors located on the target cells (eg. in the VLPO, 
EWN, RVLM) (see Figs. (2) and (4)). Since the inhibitory 
effect is mediated by the same post-synaptic receptors that 
also attenuate the activity of LC neurones in a presynaptic 
location, i.e., 2-adrenoceptors, the net effect of a 2-adreno-
ceptor agonist depends on the relative activation of pre- and 
post-synaptic receptors (see Table 1). We wish to consider 
the effect of clonidine on seven noradrenergic pathways, five 
inhibitory and two excitatory, whose roles in the regulation 
of four functions (arousal, pupil control, blood pressure, sali-
vation) have been extensively studied (see Fig. (4) and Table 
1). There are five sites where clonidine interacts with inhibi-
tory  2-adrenoceptors: LC (autoreceptors; 1), VLPO (2), 
EWN (3), RVLM (4) and salivatory nuclei (5). The “switch-
ing off” of LC activity by clonidine via activation of inhibi-
tory autoreceptors results in attenuation of both the excita-
tory (stimulatory) effects and the inhibitory effects (disin-
hibition) mediated by noradrenergic pathways arising from 
the LC. On the other hand, activation of post-synaptic inhibi-
tory 2-adrenoceptors results in potentiation of the noradren-
ergic inhibition of the target cells in the VLPO, EWN, 
RVLM and salivatory nuclei. The net effect of clonidine on 
an inhibitory noradrenergic pathway therefore will reflect the 
balance between the results of the opposing pre-synaptic and 
post-synaptic effects: if the pre-synaptic effect predominates, 
the result will be attenuation of the function and if the post-
synaptic effect predominates, the effect will be the augmen-
tation of the function. 2-Adrenoceptor antagonists (e.g., 
yohimbine) exert effects on the four functions studied which 
are opposite to those of the agonists, reflecting the blockade 
of both autoreceptors and post-synaptic receptors. 
3.1.1.1. Arousal
2-Adrenoceptor agonists have potent sedative effects 
due to the activation of the autoreceptors on LC neurones 
resulting in the “switching off” of the activity of these neu-
rones. The reduction in LC activity leads to the attenuation 
of the noradrenergic stimulation of the cerebral cortex and 
disinhibition of the VLPO which in turn leads to increased 
inhibition of the wakefulness-promoting histaminergic path-
ways originating from the tuberomamillary nucleus (TMN; 
see 1.1 above and 2.2.2.1 in Part I). It should be noted, how-
ever, that 2-adrenoceptor agonists also activate inhibitory 
post-synaptic  2-adrenoceptors in the VLPO, which is ex-
pected to lead to an increase in the level of arousal. This ef-
fect usually is masked by the presynaptic effect of these 
drugs on LC neurones resulting in a sedative effect. How-
ever, in some species (cats, rats, and mice) the stimulant ef-
fect of 2.-adrenoceptor agonists has been observed (see 
3.1.1.6, below). The sedative effect of clonidine in humans is 
well demonstrated in the laboratory [182, 184, 296, 342, 379, 
421, 486], and it is a known drawback to the clinical use of 
this drug as an anti-hypertensive agent [45, 261]. Other 2-
adrenoceptor agonists, for example dexmedetomidine, have 
also been shown to have pronounced sleep-promoting effects 
[269, 388], and this drug is used clinically as an anaesthetic. 
Interestingly, the opioid analgesic tramadol also possesses 
2-adrenoceptor stimulating activity and completely inhibits 
LC activity [31], and has been shown to be associated with 
sedation as a side effect [243, 249]. These drugs have been 
shown to promote SWS [99]. In contrast to clonidine, the 2-
adrenoceptor antagonist yohimbine has been shown to pos-
sess some alerting effects [342], and the increase in wakeful-
ness has been demonstrated to be associated with cortical 
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3.1.1.2. Pupil Control
2-Adrenoceptor activation in the LC leads to a reduction 
in sympathetically-mediated pupil dilatation due to attenua-
tion of the activity of the coeruleo-spinal pathway and also a 
reduction in noradrenergically-mediated inhibition of the 
EWN (See Fig. (4)). Post-synaptic receptors in the EWN are 
also stimulated by 2-adrenoceptor agonists resulting in an 
increase in noradrenergic inhibition of the EWN. The pupil-
lary effects of clonidine indicate that in man the pre-synaptic 
effect of the drug is likely to predominate (see Table 1). 2-
Adrenoceptor agonists cause a reduction in pupil diameter 
(miosis); [184, 341, 379]. It has been shown that this effect is 
more pronounced in light than in darkness, consistent with 
attenuation of the noradrenergic inhibition of parasympa-
thetic outflow to the iris [444]. In agreement with this obser-
vation, it has been shown that clonidine [39] and dexmede-
tomidine [238] enhance the amplitude of the light reflex re-
sponse. Remarkably,  opiate receptor agonists (eg. mor-
phine) also cause miosis in man, likely to reflect the close 
association between 2-adrenoceptors and  opiate receptors 
on LC neurones (see below, 3.1.1.6). 
  In contrast to clonidine, the 2-adrenoceptor antagonist 
yohimbine increases pupil diameter in human subjects [296, 
341, 342]. Furthermore, like the effect of clonidine on the 
pupil, this effect was light-dependent, suggesting an increase 
in the noradrenergic inhibition of parasympathetic outflow to 
the iris. 
3.1.1.3. Blood Pressure
  The LC exerts both direct and indirect effects on the ac-
tivity of preganglionic sympathetic neurones in the IML. The 
direct effect is mediated via a descending excitatory 
noradrenergic pathway, whereas the indirect effect involves 
the modulation of the activity of other premotor sympathetic 
nuclei (RVLM, caudal raphe nuclei, A5 noradrenergic neu-
rones, C1 adrenergic neurones) projecting to the IML [27, 
422] (see also Section 2.3.2 in Part I). While the noradrener-
gic projections from the LC to the serotonergic neurones of 
the caudal raphe, the A5 noradrenergic and C1 adrenergic 
neurones are likely to be excitatory, the projection to the 
RVLM is inhibitory (see Fig. (4)). The RVLM itself exerts a 
sympathoexcitatory effect via a glutamatergic projection to  
Fig. (4). The central sites of action of 2-adrenoceptor agonists (e.g., clonidine, dexmedetomidine). Nuclei: TMN, tuberomamillary nucleus; 
VLPO, ventrolateral preoptic area; LC, locus coeruleus; PT, pretectal nucleus; SN, salivatory nucleus; EWN, Edinger-Westphal nucleus; 
RVLM, rostroventrolateral medulla; IML, intermediolateral cell column; SaG, salivary ganglion; SG, sympathetic ganglion; SCG, superior 
cervical ganglion; CG, ciliary ganglion. Neurotransmitters: NA, noradrenaline; GABA, -aminobutyric acid; Glu, glutamate; ACh, acetyl-
choline. Receptors: 1 and 2, adrenoceptor subtypes. Neuronal connections are indicated by arrows: solid lines, excitatory; dotted lines, 
inhibitory. The sites at which the LC exerts an inhibitory influence are indicated by numbers: 1. autoreceptors on LC neurones, 2. VLPO, 3. 
EWN, 4. RVLM, 5. SN. For the effects of the consequences of alterations of LC activity on arousal and autonomic function, see text. 
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the IML (see 2.3.2.1, Part I). Therefore, the direct noradren-
ergic projection to the IML and the indirect projection via
the RVLM have opposing effects on blood pressure: the ef-
fect of the stimulation of preganglionic sympathetic neurones 
is counteracted by the removal of the sympathoexcitatory 
influence of the RVLM. 2-Adrenoceptor agonists have ro-
bust hypotensive effects due to the summation of their direct 
sympatholytic effect resulting from simulation of presynaptic 
autoreceptors and augmentation of the noradrenergic inhibi-
tion of the RVLM resulting from activation of post-synaptic 
2-adrenoceptors in this nucleus (see Table 1). The hypoten-
sive effects of clonidine are well documented [15, 45, 126, 
183, 185, 261, 296, 342, 379, 421, 486]. Furthermore, cloni-
dine is marketed as an effective anti-hypertensive drug. 
  The role of the RVLM in mediating the hypotensive ef-
fect of 2-adrenoceptor agonists is well demonstrated [47, 
163, 238]. Indeed, microinjection of clonidine directly into 
the RVLM results in hypotension and it is suggested that 
these neurones are tonically inhibited by 2-adrenoceptor 
activation [474]. The input from the LC is also believed to 
contribute to the baroreceptor reflex pathway outlined above 
through activation of these 2-adrenoceptors [154, 308], and 
this is supported by studies of 2A knockout mice that dem-
onstrate impaired baroreceptor reflex function [308]. Other 
2-adrenoceptor agonists, such as dexmedetomidine also 
exert a pronounced depressor effect [135, 269]. The reduc-
tion in heart rate and blood pressure by dexmedetomidine 
has been found to result from a reduction in sympathetic 
activity [269] and an augmentation of parasympathetic activ-
ity [336], consistent with LC inactivation. 
  Again, yohimbine modifies blood pressure in a direction 
that is opposite to that produced by clonidine: pressor re-
sponses have been reported [148, 204, 342, 483], consistent 
with disinhibition of pre-synaptic autoreceptors in the LC 
and post-synaptic inhibitory receptors in the RVLM. The 
involvement of the RVLM in the hypertensive action of 2-
adrenoceptor antagonists is highlighted by the observation 
that microinjection of methoxy-idazoxan into this area of the 
brainstem resulted in an increase in blood pressure [474]. 
  It should be noted that 2-adrenoceptors also occur in 
peripheral blood vessels where they mediate a vasoconstric-
tor effect [77, 299]. The vasoconstrictor effect of clonidine, 
however, does not lead to an increase in systemic blood pres-
sure since its effect on blood pressure is superseded by the 
central sympathoinhibitory effect of the drug. However, 
when the influence of central sympathoinhibition is disrupted 
due to lesions of the spinal cord, clonidine evokes an in-
crease in blood pressure due to its peripheral vasoconstrictor 
effect [393]. 
3.1.1.4. Salivation
  Salivary glands are controlled mainly by a parasympa-
thetic innervation, the preganglionic neurones in the saliva-
Table 1.  Effects of 2-Adrenoceptor Agonists on Central Noradrenergic Pathways 
2-Adrenoceptors 
Activated 
Pathway 
Pre- Post- 
Effect on Pathway  Effect Mediated by Pathway  Net Effect 
LC  VLPO  ++  +  Inhibition  Arousal  
LC  Cortex  ++  0  Stimulation  Arousal  
Arousal 
LC  EWN
1 ++ +  Inhibition   Pupil  Diameter  
LC  IML
1 ++  0  Stimulation   Pupil  Diameter  
Pupil Diameter 
LC  EWN
2 +  ++  Inhibition   Pupil  Diameter  
LC  IML
2 ++  0  Stimulation   Pupil  Diameter  
Pupil Diameter 
LC  RVLM  ++  +++  Inhibition  Blood  Pressure  
LC  IML  ++  0  Stimulation  Blood  Pressure  
Blood Pressure 
LC  Saliv. Nucl.  ++  +++  Inhibition  Salivation   Salivation  
1In man, dog and rabbit 
2In cat, rat and mouse 
Abbreviations:
EWN Edinger-Westphal  nucleus 
IML  intermediolateral cell column of the spinal cord 
LC locus  coeruleus 
RVLM rostroventrolateral  medulla 
Saliv. Nucl.  salivatory nuclei 
VLPO  ventrolateral preoptic nucleus 
Pre pre-synaptic 
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tory nuclei being located in the brainstem (see 2.3.1.2, part 
I). The LC exerts an inhibitory influence on these neurones. 
Clonidine and other 2-adrenoceptor agonists lead to a sub-
stantial reduction in salivary output [15, 45, 184, 207, 261, 
342, 379, 388, 421, 446, 486] consistent with the preferential 
activation of post-synaptic 2-adrenoceptors on salivatory 
neurones (see Table 1). On the other hand, 2-adrenoceptor 
antagonists like yohimbine lead to hypersalivation by block-
ing inhibitory 2-adrenoceptors on salivatory neurones and 
thus attenuating noradrenergic inhibition of the activity of 
these neurones [204, 292, 342, 446]. It should be noted, 
however, that 2-adrenoceptor agonists may reduce and 2-
adrenoceptor antagonists may enhance salivation not only by 
interacting with 2-adrenoceptors on preganglionic neurones 
in the salivatory nuclei but also with release inhibiting 2-
adrenoceptors on the terminals of postganglionic cholinergic 
neurones in the salivary glands [292, 446].  
3.1.1.5. Temperature
  There is evidence that the VLPO is intimately involved in 
temperature regulation [387] and also that this structure re-
ceives a dense noradrenergic innervation from the LC (see 
2.2.2.1, Part I). Interestingly, the LC is involved in modulat-
ing the hypothalamic regulation of body temperature. It has 
been reported that the LC is involved in lipopolysaccharide-
induced fever [362], which is attenuated by LC lesions [9]. 
Furthermore, LC lesions reduce brain temperature [142] and 
hypothermia induced by hypoxia [112].  
  Clonidine, probably due to a reduction in LC activity, 
leads to a fall in body temperature both in experimental ani-
mals [241, 366, 461, 511] and humans [15, 138]. The hypo-
thermic effect of clonidine is antagonised by yohimbine 
[366, 461] and by high ambient temperature, leading to an 
increase in body temperature [15]. 
3.1.1.6. 2-Adrenoceptor Associations
Opiate Receptors
@-Opiate receptors occur on LC neurones (see 3.2 in Part 
I), and opiate peptides (enkephalins, dynorphins) are highly 
concentrated in the LC [120, 297, 513]. It has been shown 
that@-opiate receptors are co-localised with 2-adrenoceptors 
in the LC and their activation results in cellular inhibition via
a shared potassium channel [75, 121]; see also 3.2, Part I). 
Morphine, like clonidine, reduces LC neurone activity [395] 
and induces synchronous oscillatory discharges [518]. There-
fore, it is not surprising that there is a considerable pharma-
cological overlap between the actions of 2-adrenoceptor and 
opiate receptor-selective agonists. Thus, it has been reported 
that chronic treatment with morphine results in up-regulation 
of 2-adrenoceptors in the brain [155].  
  Morphine, like clonidine, is highly sedative in man, and 
this effect is likely to be due to attenuation of the activity of 
the LC (see Fig. (4) and Table 1). Indeed, microinjection of 
morphine directly into the LC has been found to reduce 
arousal, observed as an increase in SWS [131]. Other opiate 
receptor agonists have also been found to produce sedation 
(oxycodone [476], tramadol [243, 249], codeine [277]). 
  Morphine, like clonidine, has been observed to reduce 
pupil diameter in man [104, 179, 225, 479], and a ‘pinpoint 
pupil’ is a clinical hallmark of opiate addiction. This effect 
of morphine is consistent with a decrease in LC activity lead-
ing to the disinhibtion of the parasympathetic light reflex 
mechanism. Other opiates share this effect (oxycodone 
[476], tramadol [225, 512], codeine [225, 479]). The close 
association between 2-adrenoceptors and @-opiate receptors 
in the pupil control system is highlighted by the observation 
that the 2-adrenoceptor antagonist yohimbine can antago-
nise the mydriatic effect (see 3.2.6, below) of morphine in 
the rat [224]. 
Table 2.  Effects of Noradrenaline Reuptake Inhibitors on Central Noradrenergic Pathways 
Pathway Effect  on   
Pathway 
Effect Mediated by Pathway  Net Effect 
LC  VLPO  Inhibition  Arousal  
LC  Cortex  Stimulation  Arousal  
Arousal 
LC  EWN  Inhibition  Pupil  Diameter  
LC  IML  Stimulation  Pupil  Diameter  
Pupil Diameter 
LC  RVLM  Inhibition  Blood  Pressure  
LC  IML  Stimulation  Blood  Pressure  
Blood Pressure 
(minor change) 
LC  Saliv. Nucl.  Inhibition  Salivation   Salivation  
Abbreviations: 
EWN Edinger-Westphal  nucleus 
IML  intermediolateral cell column of the spinal cord 
LC locus  coeruleus 
RVLM rostroventrolateral  medulla 
Saliv. Nucl.  salivatory nuclei 
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  An important therapeutic implication of the pharmacol-
ogical association between 2-adrenoceptor and ?-opiate 
receptor mediated mechanisms is the usefulness of the 2-
adrenceptor agonists clonidine and lofexidine to alleviate the 
opiate withdrawal syndrome [143]. Indeed, it has been 
shown that the LC plays an important role in the processes 
underlying opiate withdrawal [20, 228, 236]. 
Imidazoline Receptors
  Clonidine and some other 2-adrenoceptor agonists with 
an imidazoline structure may interact not only with 2-
adrenoceptors but also with imidazoline receptors [46, 329]. 
Imidazoline receptors have been subdivided into three sub-
types (I1, I2 and I3) [165]. I1-imidazoline receptors have been 
shown to occur in the RVLM, and it has been proposed that 
these receptors are the most important in mediating the car-
diovascular effects of I1-receptor agonists, such as moxo-
nidine. The co-localisation of 2-adrenoceptors and imida-
zoline receptors may be restricted to the RVLM since imida-
zoline receptors have not been identified in the LC [447] and 
there is evidence suggesting that they may also be absent 
from salivatory nuclei since moxonidine does not reduce 
salivation [156]. The depressor effect of non-selective drugs, 
such as clonidine, would reflect an action both at imidazoline 
receptors and 2-adrenoceptors in the RVLM [156] and at 2-
adrenoceptors in the LC. On the other hand, selective (non-
imidazoline) antihypertensive drugs would exert their de-
pressor effect by stimulating 2-adrenoceptors in the LC. It 
should be noted, however, that the nature of imidazoline 
receptors as an entity has been questioned and the relation-
ship to 2-adrenoceptors remains controversial [164, 229]. 
3.1.1.7. Relationship between Pre-synaptic and Post-
synaptic Effects
2-Adrenoceptors and ?-opiate receptors occur both pre-
synaptically in the LC and post-synaptically on target cells 
receiving a noradrenergic innervation from the LC (see Fig. 
(4)). The effect of agonists acting at these receptors will be 
determined by the relationship of the effects resulting from 
the activation of receptors at the pre-synaptic and post-
synaptic sites. In the case of arousal and pupil diameter regu-
lation, the action of the agonists at the two sites leads to op-
posing effects: activation of 2-adrenoceptors or ?-opiate 
receptors in the LC results in sedation and pupil constriction, 
whereas activation of the same receptors in the target cells 
(VLPO and EWN, respectively) leads to increase in alertness 
and pupil dilatation. Interestingly there is a remarkable spe-
cies difference regarding the action of 2-adrenoceptor and 
?-opiate receptor agonists on arousal and pupil diameter, and 
this species difference is likely to reflect the preponderance 
of the action of these drugs at either pre-synaptic or post-
synaptic receptors (see Table 3). Thus, while the 2-adreno-
ceptor and ?-opiate receptor agonists are uniformly sedative 
in man, dog and rabbit, they often have alerting effects, usu-
ally demonstrated as EEG activation, in cats, rats and mice. 
It should be noted; however, that sedative effects of 2-
adrenoceptor agonists have also been demonstrated in cats 
[280], rats [305], and mice [167], and there is evidence that 
the activation of presynaptic 2-adrenoceptors in the LC is 
responsible for this effect [168, 305]. There is also a species 
difference regarding the pupillary effect of yohimbine: whilst 
in humans it produces mydriasis, in cats and rats it evokes 
miosis [177]. 
  As pre- and post-synaptic receptors exist in all the spe-
cies studied, it is likely that in man, dog and rabbit where the 
presynaptic effect predominates this reflects the generally 
higher sensitivity of pre-synaptic autoreceptors compared to 
post-synaptic receptors, leading to preferential activation of 
pre-synaptic receptors at lower dosage levels of 2-adreno-
ceptor and ? opiate receptor agonist. The presence of post-
synaptic receptor activation in these species is highlighted by 
the observation that pupil dilatation has been observed in two 
human patients with high plasma morphine concentrations 
[397], and clonidine, while it is highly sedative in dogs at 
smaller doses, evokes behavioural stimulation at higher dos-
age levels [180]. However, in the cat, rat and the mouse 
where the post-synaptic effect usually predominates, it is 
likely that the pre-synaptic effect is masked by the conse-
quences of post-synaptic receptor activation. 
3.1.2. Drugs Interacting with Reuptake 
  Reuptake of released noradrenaline into the nerve termi-
nal is the principle way of terminating the synaptic action of 
the transmitter. Reuptake involves the operation of an active 
membrane pump (noradrenaline transporter; [10, 53, 274]. 
Inhibitors of the transporter result in attenuation of reuptake 
leading to potentiation of the effect of the transmitter on the 
post-synaptic cell. Inhibitors of noradrenaline reuptake are 
expected to enhance the post-synaptic effects of LC activa-
tion in each target area. We shall consider the same four 
functions (i.e., arousal, pupil control, blood pressure control, 
salivation) as discussed in relation to modulation by autore-
ceptors (see 3.2 above and Fig. (4)). 
  The noradrenaline transporter has been indentified on 
noradrenergic neurones in the LC using the highly selective 
noradrenaline uptake inhibitor nisoxetine [405, 456]. 
Noradrenaline uptake inhibitors can influence the removal of 
noradrenaline released from dendrites in the LC leading to 
increased activation of inhibitory autoreceptors via the in-
creased noradrenaline concentration resulting in a reduction 
in LC activity [145]. This effect, however, is likely to be 
superseded by the effect of noradrenaline uptake inhibition at 
the nerve terminals since while both amphetamine [7, 86] 
and cocaine [89, 348, 349, 350] reduce the activity of the 
LC, they also increase the concentration of noradrenaline in 
the synaptic gap at the target areas of noradrenergic termi-
nals [86] leading to increases in LC-mediated functions such 
as arousal and pupil diameter (see below).  
3.1.2.1. Arousal
  Inhibition of noradrenaline uptake at the excitatory nora-
drenergic synapses in the cerebral cortex and in wakefulness-
promoting nuclei, together with a similar action at inhibitory 
noradrenergic synapses in the VLPO, is expected to lead to 
an increase in arousal. Noradrenaline uptake inhibition in 
general has been associated with an alerting effect. Thus, it 
has been shown that the noradrenaline uptake inhibitors in-
deloxazine [403] and S33005 [62] increase alertness in ex-
perimental animals. 
  Although the psychostimulant actions of amphetamine 
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uptake of dopamine, these drugs are also potent inhibitors of 
noradrenaline reuptake [495]. These drugs produce robust 
increasesinarousal(amphetamine [157, 171]; cocaine [492]). 
The wakefulness-promoting drug modafinil, which is not 
classified as a psychostimulant, also increases alertness [184, 
187, 380]; see 3.1, above) and inhibits the reuptake of both 
dopamine and noradrenaline [262], and the site at which 
noradrenaline uptake inhibition may be most relevant has 
been identified as the inhibitory noradrenergic synapse on 
VLPO neurones [128]. 
  A number of antidepressants have been developed whose 
only or principal action is the inhibition of noradrenaline 
reuptake (e.g., reboxetine, venlafaxine, atomoxetine, du-
loxetine). Some of these drugs also have, albeit relatively 
weak, alerting effects. Reboxetine has been claimed to be an 
“activating” antidepressant improving social activity in de-
pressed patients [98] and both reboxetine and atomoxetine 
are used as alternatives to psychostimulants in the treatment 
of attention deficit hyperactivity disorder [517]. Reboxetine 
has also been shown to increase arousal and suppress REM 
sleep in rats [227]. Phentermine, an anorectic agent used in 
the treatment of obesity, also inhibits noradrenaline and do-
pamine reuptake and has been shown to increase wakeful-
ness in rats [371]. 
3.1.2.2. Pupil Control
  Inhibition of noradrenaline uptake is expected to potenti-
ate the noradrenergic excitation of preganglionic sympathetic 
neurones in the IML, the stimulant effect of noradrenline at 
the neuroeffector junction in the iris, and the noradrenergic 
inhibition of the EWN. Indeed, both amphetamine [151, 157, 
176, 351] and cocaine [202, 351, 497] have been demon-
strated to increase pupil diameter consistent with such an 
action. Furthermore, there is evidence that amphetamine-
induced pupil dilatation is related to the inhibition of para-
sympathetic output [224], consistent with an increase in the 
noradrenergic inhibition of the EWN. 
  It has been shown that both reboxetine [445] and ven-
lafaxine [41] cause an increase in pupil diameter and inhibit 
the light reflex response. Although the increase in pupil di-
ameter may simply reflect noradrenaline reuptake in the iris, 
leading to the enhancement of sympathetically-mediated 
pupil dilatation, the inhibition of the light reflex demon-
strates the involvement of an action at the noradrenergic syn-
apse on EWN neurones. Consistent with these findings, the 
predominantly noradrenergic tricyclic antidepressant de-
sipramine also increases pupil diameter [406] and inhibits 
the light reflex [459]; however, these effects may have been 
contaminated by an interaction of the drug with muscarinic 
cholinoceptors. 
3.1.2.3. Blood Pressure
  Noradrenaline uptake inhibition is expected to lead to 
augmentation of blood pressure [279], partly due to potentia-
tion of the central sympathoexcitatory effect of the noradren-
ergic input to preganglionic sympathetic neurones and partly 
to potentiation of noradrenergically-mediated vasoconstric-
tion in the periphery. This pressor effect is expected to be 
attenuated by potentiation of the noradrenergic inhibition of 
the RVLM. This attenuation is likely to be significant since 
noradrenaline reuptake inhibitors result in only moderate 
increases in blood pressure.  
  Administration of both amphetamine [59, 157, 264, 307] 
and cocaine [178, 284, 307] is associated with increases in 
Table 3.  Effects of 2-Adrenoceptor and "-Opiate Receptor Agonists on Arousal and Pupil Diameter  
Arousal Pupil  Diameter 
Pre-synaptic Action Dominant
2-adrenoceptor agonist       [182]         [39, 76, 184, 341, 379]  Man 
@-opiate receptor agonist       [131]         [225, 286, 334, 343, 344, 345] 
2-adrenoceptor agonist       [84]         [396]  Dog 
@-opiate receptor agonist       [502]          [396] 
2-adrenoceptor agonist  no information available           [8]  Rabbit 
@-opiate receptor agonist       [278]          [450] 
Post-synaptic Action Dominant
2-adrenoceptor agonist       [245]          [231, 232]  Cat 
@-opiate receptor agonist       [95, 221]          [80] 
2-adrenoceptor agonist       [357]          [137, 166, 169, 175, 231]  Rat 
@-opiate receptor agonist       [12, 484]          [224] 
2-adrenoceptor agonist       [159]          [167, 168]  Mouse 
@-opiate receptor agonist       [215]          [230] 
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blood pressure. Reboxetine [445], venlafaxine [2] and du-
loxetine [458] have all been reported to cause modest in-
creases in blood pressure.  
3.1.2.4. Salivation
  Potentiation of the noradrenergic inhibition of the saliva-
tory nuclei, as a result of noradrenaline reuptake inhibition, 
is expected to result in a reduction in salivary output. Indeed, 
both reboxetine [445] and venlafaxine [2] have been shown 
to reduce salivation. These observations show that a reduc-
tion in salivation by an antidepressant is not necessarily due 
to muscarinic cholinoceptor blockade in the salivary glands, 
as generally assumed, but may reflect the interaction of the 
drug with central noradrenergic mechanisms [445]. 
3.1.3. Drugs Interacting with Storage 
  Noradrenaline is stored in synaptic vesicles in the nerve 
terminal, and its accumulation in the storage vesicles is via
an active membrane pump (vesicular monoamine transporter 
2, VMAT2; [516]). VMAT2 is not specific for noradrena-
line, and is responsible for transporting also dopamine and 
serotonin into storage vesicles in the appropriate nerve ter-
minals. VMAT2 is inhibited by some drugs such as reserpine 
and tetrabenazine, leading to the initial release of the mono-
amine followed by depletion of the stores, resulting in reduc-
tion/cessation of release [107]. While dopaminergic neurones 
show preferential sensitivity to depletion by tetrabenazine 
[449]; [132], reserpine leads to near equal depletion of all 
three monoamines [406]. The depletion of noradrenaline 
from central noradrenergic neurones leads to the “switching 
off” of the LC system, whereas depletion of noradrenaline 
from peripheral noradrenergic neurones results in a marked 
sympatholytic action [436].  
  Early work with the depleting agents carried out in the 
1960s has described the consequences of noradrenaline de-
pletion on functions mediated by the LC system, and more 
recent information relating to the functional neuroanatomy of 
the system (see Fig. (4)) enables us to interpret these effects. 
Thus, administration of reserpine leads to sedation [436], 
which may be related to reductions in the excitatory influ-
ence of the LC on the cerebral cortex and other wakefulness-
promoting nuclei and of the noradrenergic inhibition of the 
sleep-promoting VLPO. The “switching off” of the nora-
drenergic inhibition of the EWN is expected to lead to in-
creased activity of this preganglionic parasympathetic nu-
cleus. Indeed, it has been shown that reserpine causes miosis, 
which is more pronounced at ambient illumination than in 
darkness, and potentiates the light reflex [43]. Reserpine also 
leads to marked hypotension, presumably due to the combi-
nation of its central and peripheral sympatholytic effects 
[436]. Reserpine-induced noradrenaline depletion has also 
been demonstrated to be associated with an increase in sali-
vary output [43], which is likely to be due to the removal of 
the tonic noradrenergic inhibition of salivatory nuclei. 
3.2. Drugs Indirectly Modifying LC Activity 
  As reviewed in Part I, the LC receives afferent inputs 
from a large number of sources. In this section we wish to 
restrict ourselves to reviewing modifications in LC activity 
by afferent inputs arising from the sleep-arousal network 
(see Fig. (1)). Stimulant and sedative drugs, apart from di-
rectly influencing LC activity (see 3.1, above), often exert an 
indirect effect on the LC via acting at different sites in the 
sleep-arousal network.  
3.2.1. Stimulant Drugs 
3.2.1.1. Adenosine Receptor Antagonists
  Adenosine accumulates during wakefulness and plays a 
role in the initiation of sleep, via activation of A1 and A2
adenosine receptors [117, 466]. The sleep-inducing effect of 
adenosine is mediated partly via inhibition of wakefulness-
promoting nuclei [287] and partly via stimulation of sleep-
promoting nuclei [129, 190], which are known to project to 
the LC (see Fig. (2)).  
 Caffeine is an adenosine receptor antagonist which is 
widely available and used extensively in the general popula-
tion as a wakefulness-enhancing compound. The drug pro-
duces robust increases in arousal [25, 54, 213, 335, 488, 522] 
and has been shown to enhance LC activity [28, 100]. Ad-
ministration of caffeine also produces increases in heart rate 
[194], blood pressure [194, 315, 464] and temperature [229], 
consistent with activation of the sympathetic nervous system. 
Interestingly, caffeine antagonises the sedative and auto-
nomic effects of clonidine [417], a drug known to reduce LC 
activity (see 3.1, above).  
3.2.1.2. Drugs Interacting with the Mesocoerulear Pathway
  The dopaminergic system plays an important role in the 
maintenance of arousal [258] and psychostimulants such as 
amphetamine and cocaine are potent activators of this system 
by inhibiting the dopamine transporter and facilitating do-
pamine release [48, 368]. The alerting effect of dopaminer-
gic drugs may partly be mediated via the LC since it has 
been shown that this nucleus receives excitatory inputs both 
from the VTA (mesocoerulear pathway) and vPAG (see 
3.1.4.1 and 3.1.4.4, Part I). 
 Modafinil is a novel wakefulness-promoting drug used in 
the treatment of EDS in narcolepsy [468, 469] and it has 
been shown to alleviate the EDS associated with a number of 
other conditions (PD [310]; idiopathic hypersomnia [199]; 
night shift sleep disorder [480]; obstructive sleep apnoea 
[325]; multiple sclerosis [358]; myotonic dystrophy [260]; 
depression [96]; schizophrenia [370]; sleep deprivation 
[346]; and drug-induced sedation [485]. Modafinil has been 
found to enhance the activity of the dopaminergic system by 
increasing extracellular levels of dopamine [102, 298, 499] 
possibly by an action at the dopamine transporter [262, 310]. 
Consequently, it has been proposed that modafinil may po-
tentiate LC activity via the enhancement of dopaminergic 
activity within the mesocoerulear pathway originating in the 
VTA [377, 383, 384]. It should be noted however, that mo-
dafinil failed to modify LC activity in anaesthetised animals 
[7] where the baseline firing rate of the neurones is very low. 
It has been suggested that this study should be repeated in 
awake animals where the LC fires at a higher rate and may 
be more sensitive to modafinil [383].  
  Modafinil’s pharmacological effects are consistent with 
those associated with increased LC activity (see 3.1 and Fig. 
(4), above). Modafinil has been found to increase arousal in 
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of sympathetic activation, including increases in pupil di-
ameter [184, 187. 379], heart rate and blood pressure [187, 
264, 377, 379], and body temperature [283, 346]. Interest-
ingly, there is little evidence of a concomitant decrease in 
parasympathetic activity, since light reflex amplitude and 
salivary output are not affected by the drug [184, 187, 377, 
379]. This observation suggests that the mesocoerulear 
pathway may preferentially activate the pre-sympathetic neu-
rones in the LC (see 5 and Fig. (6), below). 
 Amisulpride is an antipsychotic with an antagonistic ac-
tion at D2 dopamine receptors. D2 dopamine receptors have 
been shown to occur both pre-synaptically on dopaminergic 
neurones (autoreceptors) and post-synaptically: the pre-
synaptic receptors inhibit the firing of the neurone [21], 
whereas the post-synaptic receptors may mediate either exci-
tatory or inhibitory effects on the post-synaptic cell. The pre-
synaptic receptors are generally more sensitive to both ago-
nists and antagonists than the post-synaptic receptors, and 
amisulpride has a preferential action at the pre-synaptic auto-
receptors [291, 337]. In this respect amisulpride differs from 
most other antipsycotics which although block D2 dopamine 
receptors [222, 432], do not show any selectivity for the pre-
synaptic site [222, 291, 337]. In the case of the mesocoeru-
lear pathway, the preferential blockade of inhibitory pre-
synaptic receptors would increase the activity of the VTA 
neurones. As the dopamine released onto LC neurones is 
likely to interact with excitatory D2 dopamine receptors, the 
activity of the LC would increase leading to increase in alert-
ness. Indeed, amisulpride has been shown to possess some 
mild alerting effects [331], in contrast to antipsychotics with-
outpre-synaptic D2 dopamine receptor selectivity which have 
no alerting effect and are usually sedative in action [222].
3.2.2. Sedative Drugs 
3.2.2.1. GABA Receptors
  GABA is the major inhibitory neurotransmitter in the 
brain, and it exerts its action by interacting with three types 
of receptor (GABAA, GABAB, and GABAC). A major class 
of sedative drug, the benzodiazepines, interact with specific 
benzodiazepine receptors which are closely associated with 
the GABAA receptor. Activation of benzodiazepine receptors 
leads to potentiation of the inhibitory actions of GABA [289, 
347]. As most sleep-promoting neurones utilise GABA as 
their neurotransmitter, benzodiazepines act by enhancing the 
influence of sleep-promoting systems. 
  It has been shown that benzodiazepines reduce the firing 
rate of LC neurones [239, 382, 410], and it has been pro-
posed that the LC may play an important role in mediating 
the sedative effects of these drugs [240]. However, the re-
duction in LC activity after administration of benzodiazepi-
nes is unlikely to be due to potentiation of the inhibitory ac-
tion of GABA on LC neurones since the GABAA receptors 
on these neurones are not sensitive to benzodiazepines [71]. 
Therefore, the suppression of LC activity by benzodiazepi-
nes is likely to reflect enhancement of GABAergic inhibition 
at other sites in the sleep-arousal network, e.g., in the cere-
bral cortex and TMN, structures with excitatory inputs to the 
LC (see 3.1.1 and 3.1.3.4, Part I). The benzodiazepine diaze-
pam has been found to attenuate the stress-induced increases 
in noradrenaline turnover at sites such as the hypothalamus, 
amygdala, hippocampus and cerebral cortex [197], all areas 
which receive noradrenergic innervation originating in the 
LC. Interestingly, chronic diazepam administration enhances 
LC activity [338] and this over-activity may form part of the 
circuitry underlying benzodiazepine dependence and with-
drawal. 
  It is generally recognised that there is a close relationship 
between the level of arousal and pupil diameter: sedation is 
known to be associated with miosis, as observed for the 2-
adrenoceptor agonists and opiates (see 3.1, above), and pupil 
diameter is often used by anaesthetists to monitor the depth 
of anaesthesia (p 779-781 in ref. [254]). The anatomical sub-
strate of this relationship is likely to be the LC (see 1.3, 
above). Therefore, it is surprising that the benzodiazepines, 
while highly sedative, do not cause any change in pupil di-
ameter [186, 189], although they reduce LC activity (see 
above) and induce fluctuations in the firing rate of LC neu-
rones as reflected in the enhancement of pupillary fatigue 
waves [189]. These observations suggest that the benzodi-
azepines, apart from reducing LC activity, may also have a 
direct effect on the pupil control mechanism which masks 
the miosis expected from the reduction in LC activity. This 
mechanism has been suggested to be enhanced sympatheti-
cally-mediated mydriasis resulting from reduced inhibition 
of the IML due to potentiation of GABA-mediated inhibition 
of descending inhibitory bulbospinal pathways and inhibi-
tory interneurones [189]. 
3.2.2.2. Mesocoerulear Pathway
  As discussed above, LC activity is influenced by a do-
paminergic input from the VTA, the mesocoerulear pathway, 
operating  via D 2 dopamine receptors (see 3.2.1.2, above). 
Pre-synaptic autoreceptors play an important role in modu-
lating the activity of VTA neurones, their activation leading 
to a decrease and their inhibition to an increase in neuronal 
activity. D2 dopamine receptor agonists, with a preferential 
affinity for the autoreceptor, lead to attenuation of the dopa-
minergic facilitation of LC activity resulting in lowering of 
the level of arousal [217, 373, 377, 378, 380]. Indeed, it has 
been shown that D2 dopamine receptor agonists used in the 
treatment of PD have profound sedative effects (for example, 
pramipexole [161]; ropinirole [116]; pergolide [463]; bro-
mocriptine and cabergoline [333]; piribedil [452]: apomor-
phine [244]). These drugs are likely to exert their therapeutic 
effects via the activation of dopamine receptors within the 
striatum [217, 373]. 
 Pramipexole is a dopamine D2 receptor agonist which has 
been shown to possess robust sedative effects in healthy vol-
unteers [387, 388, 390]. However, paradoxically pramipex-
ole-induced sedation was associated with an increase rather 
than a decrease in pupil diameter as would be expected on 
the basis of reduced LC activity. The increase in pupil di-
ameter was accompanied by a reduction in light reflex ampli-
tude, indicating a reduction in the parasympathetic outflow 
to the iris. It was proposed that the mydriatic effect of pra-
mipexole might reflect the operation of a putative excitatory 
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pathway) whose “switching off” by autoreceptor stimulation 
would be responsible for the attenuation of parasympathetic 
activity [387, 388, 390]. Interestingly, this proposal is sup-
ported by the effect of the D2 autoreceptor antagonist amisul-
pride, which caused miosis and an increase in light reflex 
amplitude [388]. 
4. AGE-DEPENDENT ALTERATIONS OF LOCUS 
COERULEUS ACTIVITY 
  Neurone density within the LC decreases with age due to 
a progressive loss of noradrenergic neurones, both in animals 
[83, 246, 434] and humans [65, 265, 460, 477]. This neurone 
loss is uniformly diffuse across the LC, without preferential 
reduction in any restricted area [270]. In addition, the re-
maining neurones within the LC show shrinkage of the peri-
karya and a subsequent decrease in cell size [65, 83]. Ageing 
cells within the LC also exhibit mitochondrial and ribosomal 
alterations and these changes have been suggested to pro-
duce disruptions in the absorption of nutrients, protein syn-
thesis, energy supply, transport of materials and message 
exchange [83]. The age-dependent decline in LC activity 
may be accentuated via an indirect mechanism. The ageing 
brain also shows a reduction in orexin B-immunoreactive 
axons within the LC accompanied by a decline in tyrosine 
hydroxylase mRNA in the LC, a marker of noradrenergic 
activity [105].  
  It has been observed that the number of LC neurones 
projecting to areas such as the frontal cortex and the hippo-
campus declines with age, but that a certain degree of axonal 
branching occurs to maintain noradrenaline levels at target 
areas [196, 197, 403]. However, despite this branching, the 
loss of noradrenergic LC axons innervating the frontal cortex 
has been found to result in fewer synapses [198], and 
changes in the electrophysiological properties of the remain-
ing LC axon terminals have been observed [404]. Decreased 
binding in the LC of nisoxetine, a noradrenaline uptake in-
hibitor, has been observed in aged humans [456] and this 
decrease is likely to be related to the loss of LC neurones, 
and thus a reduction in noradrenaline transporters at nerve 
terminals. Similarly, in an aged rat nisoxetine-sensitive 
noradrenaline uptake inhibition was attenuated, again repre-
senting a decline in noradrenergic transporters at axon termi-
nals [405]. In addition to a loss of transporters, 2-adreno-
ceptor responsiveness in the LC is reduced with ageing. In 
aged rats microinjections of clonidine and yohimbine into 
the LC, where these drugs have a localised effect on presyn-
aptic inhibitory autoreceptors, do not modify alertness level, 
in contrast to the sedative and wakefulness-promoting ef-
fects, respectively, observed in younger rats [99, 312, 313]. 
Thus, these various disruptions in the functioning of the LC 
with age result in an overall deficiency in noradrenergic neu-
rotransmission [34].  
  Memory impairment in old age has been related to the 
loss of LC function with ageing [272]. For example, reduc-
tions in cortical noradrenaline transmission with age have 
been associated with deficits in spatial learning and memory 
[78] and a significant correlation has been observed between 
the extent of neurone loss in the LC with age and the degree 
of memory impairment on an inhibitory avoidance task in 
mice [246]. 
  This influence of ageing on LC activity can be observed 
in changes in pupillary function. Resting pupil diameter is 
reduced with age [37, 352, 416, 431], with pupil diameters of 
1 mm or less becoming more prevalent [423], and this is 
consistent with a deficit in the sympathetic nervous system 
resulting from reduced LC activity. A decline in the sympa-
thetic outflow to the iris in old age is further demonstrated by 
reductions in the amplitude and velocity of the darkness re-
flex response and prolongation of the recovery time of the 
light reflex response [37]. However, the parameters of the 
light reflex response may also be altered in old age [37, 352, 
390, 431], suggesting that the aging process may affect both 
the sympathetic and parasympathetic controls of the pupil. 
The role of the LC in the age-related sympathetic deficit in 
pupillary control is highlighted by the fact that there is a par-
allelism between the monotonic decline in pupil size [416] 
and cell numbers in the LC [265] with age. The age-related 
decline in LC neurone numbers is likely to be accelerated in 
AD, resulting in accentuation of the sympathetic deficits of 
pupil control present in elderly people (see 5.2, below).
5. PATHOLOGICAL ALTERATIONS OF LOCUS CO-
ERULEUS ACTIVITY 
  Alongside the physiological and pharmacological ma-
nipulations that can produce changes in the activity of the 
LC, pathological changes associated with various diseases 
can alter LC neurone functioning. Pathological changes in 
the LC have been noted in a number of neurodegenerative 
diseases, including PD [514], AD [44], Huntington’s disease 
[521], progressive supranuclear palsy [266], Lewy body dis-
ease [435], Down’s syndrome [271], Pick’s disease [13], and 
amyotrophic lateral schlerosis [318]. In this review we focus 
our attention on the most common of these: PD and AD. In 
addition, the possible contribution of disruption to LC neu-
rone function in brainstem coma is discussed. 
5.1. Parkinson’s Disease 
  PD is a progressive neurodegenerative disorder associ-
ated with motor deficits that include muscular rigidity, 
bradykinesia, resting tremor, postural instability and hypoki-
nesia. These deficits have been largely related to the degen-
eration of dopaminergic neurones in the pars compacta of the 
substantia nigra that project to the striatum, leading to a re-
duction in dopamine content within the striatum. However, 
there is evidence that the noradrenergic neurones of the LC 
are also important in this disorder [63, 136, 272]. A signifi-
cant loss of LC neurones has been observed post-mortem in 
PD [32, 133, 332, 356, 472] and also indicated by a reduc-
tion in the neuromelanin signal localised to the LC using 
MRI in living patients ([386]; see 4.5, below). Indeed, neu-
rone loss from the LC has been found to be more extensive 
than that from the substantia nigra [514], with Lewy body 
formation commencing in a number of areas including the 
LC before any pathology occurs in the substantia nigra [49, 
97].  
  In addition to a loss of LC neurones, PD is also associ-
ated with morphological changes to the surviving neurones 
in the LC, including changes in the size and shape of both 
pre- and postsynaptic components of synapses, polymor-
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of the mitochondria, swelling of the cell bodies, inclusion of 
Lewy bodies, and shortening and thinning of the dendrites 
with absent or reduced arborisations [23, 64, 332]. 
  It is known that the LC sends an excitatory noradrenergic 
projection to the striatum-projecting neurones of the substan-
tia nigra [79, 146], activating the dopaminergic neurones via
activation of 1-adrenoceptors [146]. Interestingly, lesions of 
the LC result in an increase in the loss of dopaminergic neu-
rones from the substantia nigra induced by the neurotoxin 6-
OHDA [35, 425], indicating that the noradrenergic neurones 
from the LC have a neuroprotective effect on the dopaminer-
gic neurones of the substantia nigra. In addition, in monkeys 
with MPTP induced PD, lesions of the LC impair the recov-
ery of the motor deficits that usually occurs at 9 weeks post-
treatment [276], supporting the involvement of the LC in the 
progression of PD. It, therefore, seems likely that the nora-
drenergic neurones of the LC have both neuromodulatory 
effects on dopaminergic neurones of the substantia nigra, 
important for maintaining or facilitating the nigrostriatal 
pathway, and neuroprotective effects on these dopaminergic 
neurones, resulting in neurodegeneration when the LC is 
compromised and contributing to the development of PD 
[272, 424].  
  Sleepiness in PD has been found to be related to the pa-
thology of the disease alongside any sedation induced by 
pharmacological treatment [14] and it is likely that this 
sleepiness results from the reduction in LC activity that oc-
curs as a result of the neurone loss described above. In addi-
tion, the degree of LC neurone loss has been associated with 
the incidence of dementia in PD [520] and this association 
may be related to the loss of LC neurones involved in the 
circuitry underlying executive functioning (see Part I). In 
support of this suggestion, noradrenaline levels in the LC 
have been found to be reduced post-mortem in PD patients 
who also suffered from dementia compared to PD patients 
who had no clinical signs of dementia [60]. Alongside the 
sleepiness and dementia discussed above, depression and 
anxiety in PD may also be associated with the loss of LC 
neurones, resulting from a reduction in noradrenergic inner-
vation of the limbic system [367]. 
  Pharmacological studies suggest that 2-adrenoceptor 
antagonists could be used therapeutically in an attempt to 
increase LC neurone activity in PD. For example, in a pri-
mate model of PD administration of the 2-adrenoceptor an-
tagonist idazoxan improved motor abnormalities [33]. This 
possibility requires further investigation. 
5.2. Alzheimer’s Disease 
  AD is a progressive neurodegenerative disorder associ-
ated with a decline in cognitive functions including memory, 
language, attention, judgement and executive function (for 
example, planning and organisation). These deficits have 
primarily been related to dysfunction within the cholinergic 
system, particularly in the nucleus basalis. However, there is 
considerable evidence that dysfunction within the LC is also 
important in this disorder, since a significant loss of nora-
drenergic LC neurones can be observed post-mortem [58, 63, 
64, 125, 133, 201, 259, 267, 272, 275, 433, 448, 472, 503]. 
This loss of LC neurones is greater than that observed in the 
case of normal ageing ([460]; see below) and interestingly 
there is significantly more neurone loss from the LC than 
from the cholinergic neurones in the nucleus basalis [267, 
514]. It has been proposed that LC neurone degeneration 
may contribute to the development and progression of AD, 
since in amyloid-containing amyloid precursor protein 23 
(APP23) transgenic mice, a model of AD pathology, LC 
lesions augmented amyloid plaque deposits in the projection 
areas of the LC and increased memory deficits compared to 
non-transgenic mice who also received LC lesions [172]. 
The root cause of the loss of neurones from the LC in AD is 
unclear, but may be associated with the formation of neu-
rofibrillary tangles, since neurofibrillary tangles have been 
identified within the LC [58, 503]. In addition, increased 
levels of the neurotoxic monoamine oxidase A metabolite of 
noradrenaline, 3,4-dihydroxyphenylglycolaldehyde, has been 
observed in the LC in AD and may contribute to this neurone 
loss [57]. It appears, however, that the LC neurone loss is not 
related to the over-expression of beta-amyloid protein [134]. 
  Alongside the reduction in LC neurone density, mean 
brain noradrenaline concentration is lower in AD sufferers 
than in healthy controls [181] and cortical noradrenaline lev-
els have been found to be reduced [201, 275]. In contrast, 
noradrenaline levels measured from the cerebro-spinal fluid 
are significantly higher in AD than in controls [110], and this 
may result from an increase in activity of some surviving 
neurones in order to compensate for the extensive neurode-
generation [181, 448]. Pathological changes are observable 
within these surviving LC neurones, however, where cell 
somata are reported as swollen and misshapen and dendrites 
are shorter and less branching [64]. 
  The mechanism by which LC neurone loss contributes to 
AD development is unclear. In non-disease states noradrena-
line from the LC may directly influence cell bodies of the 
nucleus basalis to increase acetylcholine release [272, 415, 
509] and may modulate cortical cholinergic transmission via
activation of 2-adrenoceptors on cholinergic terminals of 
cortically-projecting nucleus basalis neurones, again to in-
crease acetylcholine release [170]. Therefore, a reduction in 
noradrenaline release from the LC in AD would result in a 
reduction in cholinergic neurotransmission. In addition, a 
loss of cholinergic innervation of the LC has been observed 
in AD [433] and this may contribute to the reduced LC func-
tioning in AD discussed above. 
  As noradrenaline depletion studies using a neurotoxin to 
lesion the LC have found deficits in attention, learning and 
memory [272], neuronal loss in the LC may contribute to the 
cognitive decline in AD. It has been reported that as patho-
logical changes in the LC occur early in AD, the early cogni-
tive changes in the disorder may be related to LC degenera-
tion [150]. LC degeneration is progressive during the course 
of the illness and there is a positive correlation between the 
duration of illness and the magnitude of LC neurone loss 
[133]. Furthermore, there are also positive correlations be-
tween the magnitude of LC neurone loss and dementia sever-
ity [44] and between the reduction in noradrenaline concen-
tration in the cerebral cortex and cognitive impairment [275]. 
Interestingly, patients with a history of depression had sig-
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LC may thus be a possible therapeutic target to alleviate the 
cognitive deficits in AD. It has been reported that transcuta-
neous electrical nerve stimulation (TENS), using the same 
stimulus parameters which have been shown to increase LC 
activity in experimental animals, results in improvements of 
both cognitive functions and behaviour in patients suffering 
from AD [389]. This observation opens the way to consider 
retrograde vagus nerve stimulation as a possible indication 
for AD, and indeed preliminary reports indicate that this pro-
cedure may have beneficial effects on cognitive functions in 
patients suffering from AD [285, 414]. The electrical stimu-
lation of the left vagus nerve is well established as a thera-
peutic procedure both in epilepsy [149] and treatment-
resistant depression [301]. Interestingly, it has been shown 
that vagus nerve stimulation leads to increases in the firing 
rates of noradrenergic neurones in the LC and serotonergic 
neurones in the dorsal raphe nucleus [103]. 
  It may be expected that a reduction in LC activity, which 
is likely to occur from the earliest stages of AD, would be 
reflected in deficits in a number of LC-mediated functions. 
Indeed, there is evidence of a sympathetic deficit in AD pa-
tients, affecting sweat gland activity and pupillary function. 
A reduction in impulse traffic in sympathetic fibres innervat-
ing eccrine sweat glands results in hyposensitivity of the 
glands to intradermally injected carbachol ([443], see also 
2.2.2), and it has been reported that patients suffering AD 
show reduced responsiveness of their sweat glands to car-
bachol, compared to age- and sex-matched control subjects 
[235]. It has also been reported that patients suffering from 
mild/moderate AD have reduced pupil diameters and attenu-
ated darkness reflex responses in comparison to age matched 
healthy controls, indicating reduced sympathetic function, 
consistent with a reduction in LC activity [353]. 
  Patients with AD may show enhanced sensitivity of their 
pupils to the mydriatic effect of topically applied tropi-
camide, a muscarinic cholinoceptor antagonist [391]. Al-
though this observation has been related to degenerative 
changes in the EWN seen in AD [392], it is more likely to 
reflect the loss of LC activity. It has recently been found that 
administration of clonidine, a drug known to “switch off” LC 
activity (see 3.1.1), results in augmentation of tropicamide-
evoked mydriasis in healthy volunteers [188]. This observa-
tion also suggests that administration of a single dose of 
clonidine is likely to enhance the sensitivity of the “tropi-
camide” eye-drop test in AD, providing possible means for 
the early detection of developing brain degeneration [188]. 
  Reduction in LC activity in AD is also expected to be 
reflected in the level of alertness of AD patients. Indeed, it 
has been reported that patients suffering from AD have re-
duced flicker fusion frequency thresholds compared to age-
matched healthy controls [87, 88], indicating a decline in the 
level of arousal, consistent with a reduction in LC activity in 
AD. 
  It has been reported that both saccadic [118, 183, 184, 
191] and smooth pursuit [119, 191, 234, 510] eye move-
ments are impaired in AD. Eye movements are controlled by 
an intricate neural network involving brainstem nuclei and 
the cerebral cortex and degenerative changes in several sites 
in this network may explain the eye movement deficiency 
reported in AD [372]. However, it is of interest that a reduc-
tion in LC activity may also contribute to the eye movement 
disorders. The LC sends an excitatory output to the oculomo-
tor nuclear complex (see 2.3.5.4, Part I), and there is phar-
macological evidence that drugs modifying LC activity lead 
to alterations in eye movements. Thus, 2-adrenoceptor ago-
nists (dexmedetomidine, clonidine), which “switch off” the 
LC, reduce peak saccadic velocity in healthy volunteers [1, 
139, 154], whilst 2-adrenoceptor antagonists (ethoxyida-
zoxan), which potentiate LC activity, increase peak saccadic 
velocity in healthy volunteers [81]. Furthermore, sedative 
drugs in general reduce peak saccadic velocity [24, 473], 
consistent with a reduction in LC activity evoked by these 
drugs.  
5.3. Brainstem Coma 
  The presence of coma following brainstem stroke has 
been linked to lesions of nuclei located in the pons, in par-
ticular with the LC [330]. In this study, patients with brain-
stem damage without coma had no damage, or very little 
unilateral damage, to these areas in the tegmentum including 
the LC. Thus, lesions in the upper pons which include the LC 
are implicated in the causation of coma in humans, consis-
tent with the wakefulness-promoting functions of this nu-
cleus. 
5.4. Imaging of Neuromelanin in Humans 
  The LC and the substantia nigra are visible to the naked 
eye when the brain is dissected since both nuclei contain a 
pigment, neuromelanin [515, 519]. It has recently become 
possible to image the substantia nigra [386] and the LC [386, 
399, 400] see Fig. (5)) using neuromelanin-magnetic reso-
nance imaging. The contrast ratio between the neuromelanin-
containing nuclei and the surrounding brain tissue is used as 
an index of neuromelanin concentration. Preliminary reports 
indicate that in PD the neuromelanin content is reduced both 
in the substantia nigra and the LC compared to healthy con-
trols [386] and the neuromelanin content in the LC shows an 
inverted-U relationship with age, highest levels being ob-
servable in middle aged individuals [399]. Furthermore, a 
reduction in neuromelanin signal in the LC has been reported 
in patients suffering from depression [400]. These encourag-
ing reports should be followed up by further work aimed at 
clarifying the relationship between neuromelanin content and 
cell numbers in the LC, since while the number of LC neu-
rones has been reported to decline with age and the devel-
opment of neurodegenerative diseases (see above), the neu-
romelanin concentration of pigmented nuclei seems to in-
crease with the advancement of age [515]. Finally, the most 
important question is how neuromelanin content can be re-
lated to LC activity. 
CONCLUSIONS 
  It is apparent that manipulations of a physiological, 
pharmacological or pathological nature produce consistent 
alterations in LC activity, affecting both arousal state and 
autonomic function. Clearly, the LC is a major nucleus in the 
central regulation of these functions and reliable outcomes 
from changes in LC activity can be observed, especially on 
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tions discussed above (anxiety, noxious/painful stimulation, 
extreme ambient temperature) increase LC activity and thus 
result in heightened arousal and changes in autonomic func-
tion consistent with sympathetic activation (for example, 
pupil dilatation). Similarly, administration of drugs such as 
stimulants,  2-adrenoceptor antagonists and noradrenaline 
uptake inhibitors increase the influence of the LC on areas 
receiving noradrenergic innervation. In contrast, administra-
tion of sedatives and 2-adrenoceptor agonists reduce LC 
activity and result in a decrease in arousal and produce sym-
patholytic effects (for example, pupil constriction). Likewise, 
LC neurone loss in aging, PD, AD, and brainstem coma re-
sults in decreases in arousal and a reduction in activity of the 
sympathetic nervous system. It is of interest to note that the 
pathological changes within the LC that occur in PD and AD 
are similar in nature and thus these disorders may form two 
poles of a spectrum of neurodegenerative disease related to 
loss of LC neurones [272, 339]. Overall it is clear that the 
LC is centrally involved in controlling the regulation of 
arousal and autonomic function, and thus any manipulation 
(physiological, pharmacological or pathological) which al-
ters LC activity will have consequences on aspects of this 
control.  
  The pattern of the consequences of LC activation by dif-
ferent variables suggests that there may be separate popula-
tions of LC neurones associated with sympatho-excitatory 
and parasympathetic-inhibitory effects (Fig. (6)). Thus, nox-
ious stimulation (see 2.1, above) and enhancement of the 
activity of the mesocoerulear pathway by the wakefulness-
promoting drug modafinil (see 3.2.1, above) result in the 
relatively selective activation of pre-sympathetic LC neu-
rones since these variables increase pupil diameter without 
any inhibition of the light reflex response. Indeed, modafinil 
has no influence on salivary output, a parasympathetically-
mediated function. On the other hand anxiety (see 2.2, 
above), probably via activation of the amygdala, leads to 
preferential activation of pre-parasympathetic LC neurones 
leading to inhibition of the light reflex and reduction in sali-
vation.  
Fig. (6). Schematic diagram to illustrate the hypothesis of two 
populations of locus coeruleus (LC) neurones. Sympathetic premo-
tor neurones (shown as blank area) are preferentially activated by 
noxious stimuli from collaterals of ascending pain pathways and the 
dopaminergic neurones of the ventral tegmental area (VTA) (meso-
coerulear pathway), whereas parasympathetic premotor neurones 
(shown as shaded area) are preferentially activated by anxiety via
an output to the LC from the amygdala (Amyg). The sympathetic 
premotor neurones have a stimulatory effect on sympathetic activity 
(Symp Activity) and level of arousal whereas the parasympathetic 
premotor neurones exert an inhibitory influence on parasympathetic 
activity (Para Activity) (see text for details). 
Fig. (5). Magnetic resonance image showing a cross-section of the upper pons displaying the loci coerulei (LC). A picture was taken in a
healthy human subject with the modification of the method of Sasaki et al., 2006, on a 3-tesla scanner to obtain neuromelanin signal to iden-
tify LC. The loci coerulei are shown by the small white areas in the bottom corners of the fourth cerebral ventricle, indicated by black ar-
rows. By courtesy of Professor D. Auer, Queen’s Medical Centre, Nottingham. 
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  In conclusion, recent developments in the functional neu-
roanatomy of the central noradrenergic system have enabled 
the rational interpretation of the effects of a number of cen-
trally-acting drugs. Conversely, many drugs have proved to 
be useful tools in the dissection of the complex neural net-
work regulating arousal and autonomic activity. This fruitful 
relationship between functional neuroanatomy and pharma-
cological probes is likely to grow further with the develop-
ment of neuroanatomical research tools of higher resolution 
and drugs with increasing selectivity and specificity. 
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